IF YOU ARE HAVING BREATHING PROBLEMS , HERES A GOOD PIPE TO BREATH-THROUGH TICKER (NUWE)
**Nuwellis, Inc. (NASDAQ: NUWE)** is a commercial-stage medical technology company based in Eden Prairie, Minnesota. It develops, manufactures, and commercializes devices for ultrafiltration therapy to treat fluid overload (excess fluid in the body), mainly in patients with heart failure, critical care needs, or cardiorenal conditions.
Its flagship products are the **Aquadex FlexFlow** and **Aquadex SmartFlow** systems. These remove excess salt and water when diuretics fail. The systems are indicated for adult and pediatric patients weighing 20 kg or more. The company is expanding in pediatrics (now a major revenue driver, \~50% of U.S. revenue in recent periods) and has pipeline items including label expansion efforts (targeting lower pediatric weights), patents for catheter and related tech, and the acquisition of Rendiatech for automated kidney-function monitoring (targeted U.S. introduction around 2027).
It was previously known as CHF Solutions and has undergone significant restructuring, reverse splits, dilution via offerings, and leadership changes (current CEO Mike McCormick).
What’s Moving the Stock
The stock is extremely volatile (microcap/penny stock territory with frequent large percentage swings on low absolute prices and high relative volume). Recent catalysts driving sharp upside (including multi-day moves of 90–170%+ in late July 2026) include:
* Pediatric expansion: First Aquadex SmartFlow installations at a leading Wisconsin pediatric hospital (announced \~July 28, 2026), building on prior Michigan and other placements.
* Preliminary Q2 2026 revenue: Expected +14% year-over-year for Q2 and +20% for the first half of 2026.
* Clinical validation: Acceptance of a single-center retrospective study in *Frontiers in Pediatrics* supporting an alternative anticoagulation strategy (epoprostenol) for Aquadex in critically ill kids (announced July 30, 2026). The study (UPMC Children’s Hospital data) showed maintained circuit performance without increased bleeding or vasoactive support needs.
* Other recent positives: New U.S. patent for dual-lumen catheter technology, FDA pre-submission progress on pediatric label expansion (to ≥5 kg, with 510(k) targeted by end of 2026), leadership focus on pediatrics and cash-burn reduction, and overall commercial momentum in Aquadex utilization
# Who Owns It
Institutional ownership is very low (typically \~1–5% or less in recent periods, varying with share count changes from offerings and reverse splits). The float is largely retail/public.
Notable institutional or related holders (from 13F/13G filings; positions fluctuate and can appear large in % terms due to tiny share counts post-splits):
* Armistice Capital LLC (has held significant stakes in some periods).
* Sabby Management LLC / Sabby Volatility Warrant Master Fund (previously notable,
* Insiders (management/board) hold a portion, with names like John L. Erb (long-time executive/chairman figure) appearing in historical filings.including passive 5%+ filings; has adjusted positions).
* Smaller or transient: Geode Capital Management, Tower Research Capital, Citigroup, UBS, DRW Securities, XTX Topco, and index-related funds (e.g., Fidelity Extended Market).
# Earnings Report
**Most recent full results (Q1 2026, ended March 31, reported May 12, 2026):**
* Revenue: $2.4 million (+26% YoY from $1.9 million), driven by higher console placements and circuit utilization across pediatric, heart failure, and critical care.
* Gross margin: 70.1% (up \~14 percentage points YoY), aided by pricing, mix, and contract manufacturing transition.
* Operating expenses: \~$6.0 million (up from \~$4.1 million).
* Net loss: \~$4.3–4.5 million attributable to common shareholders.
* Cash: \~$2.2 million (plus restricted) at quarter-end, no debt. Company completed capital raises (including \~$5M private placement earlier) and is targeting major cash-burn reduction (\~50% by Q4 2026).
**Preliminary Q2 2026 (announced July 27, 2026):** Expected revenue growth of +14% YoY for the quarter and +20% for H1 2026. Full Q2 results and call expected around mid-August 2026 (some sources cite \~August 11–13).
The company continues to lose money overall (TTM net losses in the tens of millions range historically) but shows sequential commercial progress and margin improvement while focusing on higher-return areas (especially pediatrics) and cost control.
# Price Prediction / Outlook-$ 17
IF YOU HAVE BETTER STOCK , PLEASE SHARE UNTIL THEN
MAY THE GODS BE WITH YOU